+34 620 10 75 37info@nanbiosis.com

Posts by Nanbiosis

You are here : Home / Articles by Nanbiosis (Page 58)

Polymers and medical applications: Success Cases of Preclinical Research

Next May 10, a conference on “Polymers and medical applications” will be held in Vizcaya, with the participation of NANBIOSIS Deputy Director, and JUMISC Scientific Director Dr. Francisco Miguel Sánchez Margallo, as guest speaker, who will give the lecture “Preclinical Research: Success Cases“

The event will count also with the expertise of Dr. Miguel Angel Martínez, Scientific Director of NANBIOSIS U13 Tissue & Scaffold Characterization Unit, talking about “Modeling and simulation in biomedical applications”

Other topics that will be discussed at the Conference will be Hydrogels, Nanogels and Nanoparticles for Controlled Release of Bioactive Substances,
The Microfluidics as a Tool for the Development of “Organ-on-a-chip and the Use of Liquid Silicone in Devices for Cell Growth.

Leartiker is a team of researchers dedicated to R+D+I, specialized in Polymer Technology and belonging to the Basque Science and Technology Network (RVCTI).

Registration is free until full capacity is reached.

More information here.

• Read More

3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 has been upgraded

The 3D cross-correlation dynamic light scattering (DLS) spectrometer of NANBIOSIS U12 Nanostructured liquid characterization unit has been upgraded with a new goniometer and last generation laser detectors and beam splitters that allow to extend the scattering angle detection range to 10-150 degrees, and enables measurements in shorter scattering lengths for highly turbid and/or concentrated samples. Non-ergodic samples (e.g. gels) can also be measured with the new configuration

The upgrade has been funded by CSIC through the grant “Special fund for the support of Scientific and Technical Services 2018” (02045)

• Read More

Why peripheral blood lymphocyte alterations can be good biomarkers to predict myocardial infarction severity

Researchers of CCMIJU led by Verónica Crisóstomo, Scientific Director of NANBIOSIS U24 Medical imaging, and Javier García Casado Scientific Director of NANBIOSIS U14 Cell Therapy unit have carried out a study study aimed to identify which are the very early immune-related biomarkers that may be used as predictors of myocardial infarction severity.

Experimental studies have been conducted by NANBIOSIS Units 14, 21, 22 and 24 of the CCMIJU, clinical test lab, animal housing, experimental operating room and medical imaging tecniciansare are recognized in the acknowledgement and funding sections of the article.

Article of reference:

Esther López, Francisco Miguel Sánchez-Margallo, Verónica Álvarez, Rebeca Blázquez, Federica Marinaro, Ana Abad, Helena Martín, Claudia Báez,Virginia Blanco,Verónica Crisóstomo and Javier García Casado “Identification of very early inflammatory markers in a porcine myocardial infarction model” BMC Veterinary Research 2019-15:91

• Read More

New tensiometer for NANBIOSIS Unit 12

The new Biolin Sigma 701 has replaced the previos KSV Sigma 700. in the equipment of NANBIOSIS U12 Nanostructured liquid characterization unit

With this new tensiometer automated and high precision measurement of surface and interfacial tensions, contact angles and critical micelle concentrations will be obtained.

The purchase of the new tensiometer has been co-funded by the CSIC through a grant received from the Scientific and Technical Services support (MEC1372).

• Read More

Infertility: Exosomal microRNAs in seminal plasma as sensitive and specific biomarkers of the presence of testicular spermatozoa for azoospermia

NANBIOSIS ICTS coordination equipment has recently received from researchers of Human Molecular Genetics Group of Bellvitge Biomedical Research Institute (IDIBELL) a publication mentioning NANBIOSIS in the Acknowledgements for its participation in the results of its investigations. The article has been publish by the journal Human Reproduction of OXFORD UNIV PRESS  with Quartile 1/ Decile 1.

The study carried out by  Maria Barcelo, Ana Mata, Lluís Bassas, and Sara Larriba demonstrates the potential of several miRNAs contained in small extracellular vesicles (sEVs) of seminal fluid as sensitive and specific biomarkers for selecting those azoospermic individuals with real chances of obtaining spermatozoa from the testicular biopsy. The nanoparticle tracking analysis was performed by the ICTS NANBIOSIS  U6 Biomaterial Processing and Nanostructuring Unit.

Article of reference:

Maria Barceló, Ana Mata, Lluís Bassas and Sara Larriba, Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue Human Reproduction, pp. 1–12, 2018doi:10.1093/humrep/dey072

• Read More

NANOMOL group, coordinator of NANBIOSIS Unit 6 collaborates with the VHIR in the developement of a new nanomedicine for the treatment of a childhood cancer

Within the MOTHER project (Molecule-based materials and supramolecular organizations for therapy, diagnosis and tissue engineering), the NANOMOL group from ICMAB collaborates with the Vall d’Hebron Institute of Research (VHIR), on the developement of a new nanomedicine for the treatment of high risk neuroblastoma, one of the most typical childhood cancers. Now, researchers from VHIR have identified new microRNAs that reduce the progression of this type of cancer.

The participation of NANOMOL group and NANBIOSIS unit 6 Biomaterial Processing and Nanostructuring Unit, as experts in nanoparticles and nanovesciles for nanomedicine, is on the synthesis of the adequate nanocapsules to protect, stabilize and direct this microRNAs molecules to the cancer tumours. The near future goal is to be able to administer the identified microRNAs for the treatment of high-risk neuroblastoma.

For further information

• Read More

Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 is interviewed by CIBER Bulletin

Laura M. Lechuga, group leader of the CIBER-BBN at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and Sccientific Director of NANBIOSIS Unit 4 Biodeposotion Unit explains her research in an interview to CIBER Bulletin

• Read More

The hidden brain activity

Researchers of NANBIOSIS Unit 8 Micro and nano techonlogy unit, (Institut de Microelectrònica de Barcelona-CNM-CSIC/ CIBER-BBN ), led by Anton Guimera are coauthors of recently published article in the scientific magazine Nature Materials about the hidden brain activity, entitled “High-resolution mapping of infraslow cortical brain activity enabled by graphene microtransistors “

Recording infraslow brain signals (<0.1 Hz) with microelectrodes is severely hampered by current microelectrode materials, primarily due to limitations resulting from voltage drift and high electrode impedance. Hence, most recording systems include high-pass filters that solve saturation issues but come hand in hand with loss of physiological and pathological information. In this work, we use flexible epicortical and intracortical arrays of graphene solution-gated field-effect transistors (gSGFETs) to map cortical spreading depression in rats and demonstrate that gSGFETs are able to record, with high fidelity, infraslow signals together with signals in the typical local field potential bandwidth. The wide recording bandwidth results from the direct field-effect coupling of the active transistor, in contrast to standard passive electrodes, as well as from the electrochemical inertness of graphene. Taking advantage of such functionality, we envision broad applications of gSGFET technology for monitoring infraslow brain activity both in research and in the clinic.

Article of reference:

Masvidal-Codina, E., Illa, X., Dasilva, M. et al. High-resolution mapping of infraslow cortical brain activity enabled by graphene microtransistors. Nature Mater18, 280–288 (2019). https://doi.org/10.1038/s41563-018-0249-4

• Read More

Meshes in a mess: Mesenchymal stem cell-based therapies for soft tissue reinforcement

Unit 14 of Nanbiosis of Cell Therapy, led by Javier García Casado, has published a review on advances in the development of surgical meshes combined with stem cells. The work of the Nanbiosis team has been published in the prestigious journal “Acta Biomaterialia”

• Read More

Nanobiosensors for the monitoring of brain lesions

On March 11, the first meeting of the European project ABISens “Monitoring of Acquired Brain Injury and recovery biomarkers by the combined label-free nanoSensing of multiple circulating molecules” was held at the facilities of the Catalan Institute of Nanoscience and Nanotechnology ICN2.

This new initiative aims to offer a new platform for photonic nanobiosensors that allows the identification and quantification of multiple brain biomarkers in blood with high sensitivity and in a short time. The new platform will use nanophotonic circuits in combination with the chemistry of oligonucleotides.

Two units of NANBIOSIS participate in the project Unit 4 Biodeposition and Biodetection Unit, led by Laura Lechuga, as coordinator of the EURONANOMED-III project and recenttly incorporated unit 29 of Oligonucleotide Synthesis Platform lead by Ramón Eritja. The project, which will also work with researchers from the Maugeri Spa Società Benefit Clinical Institute (ICSM) of Italy and researchers from the University of Bordeaux (UNIBO) in France, responds to the clinical need to evaluate patients after brain injuries that cause disabilities serious. The final tool developed after the project will be validated in samples of 40 patients with brain injury.

The project, which will last for 3 years and has a budget of more than € 700,000, is financed by the call for transnational research projects in nanomedicine, within the framework of the European research network ERA-NET Cofund EURONANOMED III (2016- 2021) “European Innovative Research & Technological Development Projects in Nanomedicine (ENM III)”. At a national level, the Carlos III Health Institute will be the entity that will finance the coordinating group of CIBER-BBN

• Read More